Klaus Boeker

1.4k total citations
30 papers, 1.0k citations indexed

About

Klaus Boeker is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Klaus Boeker has authored 30 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Hepatology, 25 papers in Epidemiology and 2 papers in Surgery. Recurrent topics in Klaus Boeker's work include Hepatitis C virus research (24 papers), Liver Disease Diagnosis and Treatment (19 papers) and Hepatitis B Virus Studies (14 papers). Klaus Boeker is often cited by papers focused on Hepatitis C virus research (24 papers), Liver Disease Diagnosis and Treatment (19 papers) and Hepatitis B Virus Studies (14 papers). Klaus Boeker collaborates with scholars based in Germany, United States and Australia. Klaus Boeker's co-authors include Michael P. Manns, Mathias Bähr, Ralf Lichtinghagen, Peer Flemming, Christian I. Haberkorn, Dirk Michels, Björn Nashan, Karl J. Oldhafer, R. Raab and Hans J. Schlitt and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Annals of Surgery.

In The Last Decade

Klaus Boeker

26 papers receiving 982 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Klaus Boeker Germany 14 686 647 251 179 81 30 1.0k
I‐Cheng Lee Taiwan 20 700 1.0× 557 0.9× 128 0.5× 285 1.6× 71 0.9× 57 1.1k
Manabu Daikoku Japan 17 686 1.0× 777 1.2× 157 0.6× 117 0.7× 16 0.2× 28 1.1k
Lau Wy Hong Kong 12 520 0.8× 330 0.5× 200 0.8× 104 0.6× 15 0.2× 23 764
June Sung Lee South Korea 16 587 0.9× 516 0.8× 222 0.9× 68 0.4× 9 0.1× 61 932
Hervé Zylberberg France 15 879 1.3× 820 1.3× 96 0.4× 73 0.4× 24 0.3× 21 1.2k
Christie Perelló Spain 11 914 1.3× 875 1.4× 63 0.3× 67 0.4× 17 0.2× 33 1.1k
Ki Tae Yoon South Korea 19 744 1.1× 767 1.2× 267 1.1× 157 0.9× 7 0.1× 77 1.2k
José Manuel Zozaya Spain 13 539 0.8× 438 0.7× 315 1.3× 92 0.5× 10 0.1× 48 816
Amr El Fouly Egypt 8 657 1.0× 427 0.7× 148 0.6× 45 0.3× 10 0.1× 14 773
Takashi Ikebe Japan 20 674 1.0× 441 0.7× 309 1.2× 167 0.9× 9 0.1× 52 913

Countries citing papers authored by Klaus Boeker

Since Specialization
Citations

This map shows the geographic impact of Klaus Boeker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaus Boeker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaus Boeker more than expected).

Fields of papers citing papers by Klaus Boeker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaus Boeker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaus Boeker. The network helps show where Klaus Boeker may publish in the future.

Co-authorship network of co-authors of Klaus Boeker

This figure shows the co-authorship network connecting the top 25 collaborators of Klaus Boeker. A scholar is included among the top collaborators of Klaus Boeker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klaus Boeker. Klaus Boeker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Rau, Monika, Peter Buggisch, Stefan Mauss, et al.. (2022). Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry. PLoS ONE. 17(6). e0264741–e0264741. 5 indexed citations
3.
Tacke, Frank, Klaus Boeker, Hartwig Klinker, et al.. (2019). Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs. Liver International. 40(3). 539–548. 22 indexed citations
4.
Christensen, Stefan, Peter Buggisch, Klaus Boeker, et al.. (2018). Scaling up HCV-DAA treatment in patients on opioid substitution therapy (OST) – does alcohol and cannabis diminish cure rates? Data from the German Hepatitis C-Registry (DHC-R). Journal of Hepatology. 68. S21–S22. 2 indexed citations
5.
Buggisch, Peter, Johannes Vermehren, Stefan Mauss, et al.. (2017). Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. Journal of Hepatology. 68(4). 663–671. 42 indexed citations
6.
Petersen, Jörg, R Heyne, Stefan Mauss, et al.. (2015). Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany. Digestive Diseases and Sciences. 61(10). 3061–3071. 34 indexed citations
7.
8.
Boeker, Klaus, Christoph Eisenbach, Bernd Moeller, et al.. (2013). 871 REAL-WORLD EFFICACY AND SAFETY OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY. Journal of Hepatology. 58. S357–S358. 1 indexed citations
9.
Bähr, Mathias, et al.. (2003). Cytokine gene polymorphisms and the susceptibility to liver cirrhosis in patients with chronic hepatitis C. Liver International. 23(6). 420–425. 35 indexed citations
10.
Rosenau, Jens, Mathias Bähr, Reinhard von Wasielewski, et al.. (2002). Ki67, E-CADHERIN, AND p53 AS PROGNOSTIC INDICATORS OF LONG-TERM OUTCOME AFTER LIVER TRANSPLANTATION FOR METASTATIC NEUROENDOCRINE TUMORS. Transplantation. 73(3). 386–394. 136 indexed citations
11.
Boeker, Klaus, Christian I. Haberkorn, Dirk Michels, et al.. (2002). Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clinica Chimica Acta. 316(1-2). 71–81. 115 indexed citations
12.
Rosenau, Jens, Hans L. Tillmann, Mathias Bähr, et al.. (2001). Successful hepatitis B reinfection prophylaxis with lamivudine and hepatitis B immune globulin in patients with positive HBV-DNA at time of liver transplantation. Transplantation Proceedings. 33(7-8). 3637–3638. 11 indexed citations
13.
Lichtinghagen, Ralf, Dirk Michels, Christian I. Haberkorn, et al.. (2001). Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C. Journal of Hepatology. 34(2). 239–247. 109 indexed citations
14.
Boeker, Klaus. (2001). Treatment of Acute Liver Failure. Metabolic Brain Disease. 16(1-2). 103–117.
15.
Lichtinghagen, Ralf, Thomas Seifert‐Held, Christian I. Haberkorn, et al.. (2000). Expression of Matrix Metalloproteinase-2 and -9 and Their Inhibitors in Peripheral Blood Cells of Patients with Chronic Hepatitis C. Clinical Chemistry. 46(2). 183–192. 57 indexed citations
16.
Schlitt, Hans J., Michael Neipp, Arved Weimann, et al.. (1999). Recurrence Patterns of Hepatocellular and Fibrolamellar Carcinoma After Liver Transplantation. Journal of Clinical Oncology. 17(1). 324–324. 154 indexed citations
17.
Schlitt, Hans J., Peter N. Meier, Björn Nashan, et al.. (1999). Reconstructive Surgery for Ischemic-Type Lesions at the Bile Duct Bifurcation After Liver Transplantation. Annals of Surgery. 229(1). 137–145. 57 indexed citations
18.
Wedemeyer, Heiner, Klaus Pethig, Doris Wagner, et al.. (1998). LONG-TERM OUTCOME OF CHRONIC HEPATITIS B IN HEART TRANSPLANT RECIPIENTS. Transplantation. 66(10). 1347–1353. 47 indexed citations
19.
Luettig, Birgit, Klaus Boeker, Hans Will, et al.. (1998). The antinuclear autoantibodies Sp100 and gp210 persist after orthotopic liver transplantation in patients with primary biliary cirrhosis. Journal of Hepatology. 28(5). 824–828. 33 indexed citations
20.
Jaeckel, Elmar, Martin Krueger, Hartmut Schmidt, et al.. (1998). Prolonged therapy of recurrent hepatitis B-infection after liver transplantation with nucleoside analogues. Journal of Hepatology. 28. 115–115. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by I‐Cheng Lee Breakdown of academic impact, for papers by Manabu Daikoku Breakdown of academic impact, for papers by Lau Wy Breakdown of academic impact, for papers by June Sung Lee Breakdown of academic impact, for papers by Hervé Zylberberg Breakdown of academic impact, for papers by Christie Perelló Breakdown of academic impact, for papers by Ki Tae Yoon Breakdown of academic impact, for papers by José Manuel Zozaya Breakdown of academic impact, for papers by Amr El Fouly Breakdown of academic impact, for papers by Takashi Ikebe
Rankless by CCL
2026